Navigation Links
WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan
Date:2/19/2013

o be partnering in a joint commercial effort with QIAGEN to bring our products to the research and industrial communities in Japan," added Ivan Trifunovich , President and CEO of WaferGen.  "Our product lines are highly complementary, together providing a total solution to our customers' needs.  Since our July, 2012 launch of our MyDesign open format instrument, we have received enthusiastically positive reviews from our early test sites and commercial customers in the US and Europe.  In conjunction with our highly-regarded partner, we look forward to building on these results in Japan.  We are confident that our three-part value proposition – platform flexibility, cost-effectiveness, and no need for pre-amplification – will be strong drivers of customers' interest," Trifunovich added. 

Under the terms of the agreement, QIAGEN and WaferGen will promote and market each other's products in Japan, specifically WaferGen's SmartChip platform and QIAGEN 's NGS platform which is currently in an advanced stage of development. This breakthrough next-generation benchtop sequencer is one element of QIAGEN's initiative to create integrated NGS workflows that combine innovative instrumentation and consumables into a sample-to-result offering planned for launch later this year. The two teams will be working closely together in terms of developing the overall strategy and tactical plan that will maximize the commercial opportunity for both companies. 

About WaferGen and the SmartChip Real-Time PCR System

WaferGen Bio-systems, Inc. is an innovative life science company that offers the SmartChip Real-Time PCR System—a next-generation genetic analysis platform for profiling and validating thousands of molecular biomarkers in parallel. It provides a range of high-throughput capabilities including microRNA and mRNA gene expression prof
'/>"/>

SOURCE WaferGen Biosystems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
2. WaferGen to Present Corporate Overview at Oppenheimer Healthcare Conference
3. WaferGen to Present Corporate Overview at 5th Annual OneMedForum San Francisco 2012
4. WaferGen Bio-systems Announces Open Format qPCR Platform and Strategic Realignment
5. WaferGen Bio-systems Awarded 1 Million Euro Grant by the Luxembourg Government to expand its European Operations
6. WaferGens MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center
7. QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
8. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
9. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
10. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
11. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... -- S&P Capital IQ (MHFI) announced today that it ... Therapeutics Holdings Inc . MabVax Therapeutics ... focused on the development of vaccine and antibody-based therapies ... cancer. MabVax has discovered a pipeline of human monoclonal ... by patients who have been immunized against targeted cancers. ...
(Date:2/26/2015)... Mass., Feb. 26, 2015   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... provided 2015 goals, other key objectives, and financial ... call today at 4:30 p.m. EST to review ... update.  To participate in today,s call by telephone, ...
(Date:2/26/2015)... The Movement for Indefinite Life Extension ... extension technologies and awareness. The event is taking place ... March 21st 2015, in a live Google Hangout broadcast ... Founder of MILE, says, “Our lives are in our ... for Indefinite Life Extension is raising awareness about bio-sciences ...
(Date:2/26/2015)... Feb. 26, 2015 BioEnterprise today announced that ... attracted more than $2 billion in growth funding during ... national investors, strategic sources, state – including the Ohio ... the $2 billion has been raised in the past ... the heels of the BioEnterprise Midwest Healthcare Growth ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... (NASDAQ: GPRO ) announced today that the Company ... April 28, 2011 at approximately 4:00 pm Eastern Time (ET). ... management at 4:30 pm ET.   The conference ... the investors section of the Company,s web site at ...
... Proteon Therapeutics, Inc. has initiated enrollment in a ... in chronic kidney disease (CKD) patients undergoing surgery for ... study follows successful completion of a 66-patient, double-blind, placebo-controlled ... completed enrollment in July 2010. "Our lead ...
... Texas, April 14, 2011 The Wound Institute today ... dynamic reciprocity at the combined meeting of the Symposium ... Society (WHS) being held in Dallas at the Gaylord ... Presenting faculty are Dr. Ira M. Herman, tenured Professor ...
Cached Biology Technology:Gen-Probe Announces Webcast of First Quarter 2011 Earnings Conference Call 2Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients 2The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 2The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 3The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 4
(Date:2/11/2015)... , February 11, 2015 ... research report "Access Control Market by Product (Cards and ... Residential, Military and Defense, Government, Industrial, Healthcare, Education) and ... published by MarketsandMarkets, the Access Control Market ... 2020, growing at a CAGR of 10.6% ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2
... A team of Dutch researchers under the leadership of ... They weakened fear memories in human volunteers by administering ... return over the course of time. Top journal ... 2009. Until recently, it was assumed that ...
... CO More than 300 geoscientists will gather 12-13 ... Section of the Geological Society of America. The meeting ... in St. Petersburg, Florida. , Geoscientists from the University ... the meeting along with the USF Geology Alumni Society. ...
... much salt, and a University of Iowa researcher has discovered ... in a better mood. UI psychologist Kim Johnson and ... in sodium chloride, common table salt, they shy away from ... pressing a bar that stimulates a pleasant sensation in their ...
Cached Biology News:An end to fear 2Study suggests salt might be 'nature's antidepressant' 2Study suggests salt might be 'nature's antidepressant' 3
Recognizes Human Connexin 45. Due to sequence homologies, this antibody is also expected to react with canine (100% homology) and mouse (92% homology) Connexin 45. Also confirmed to work on rat C6 c...
...
... Corning CellBIND surface is produced by a ... hydrophilic surface giving more consistent, even cell ... enhances cell attachment and growth uunder difficult ... • CellBIND may provide a more ecominic ...
Mouse polyclonal antibody raised against a partial recombinant RDH5. NCBI Entrez Gene ID = 5959...
Biology Products: